

ASX Announcement

Medibio Limited – 1 February 2017



Appointment of Non Executive Director and Advisory Board Changes

Sydney, Australia – 1 February 2017: Medibio Limited (MEB or the Company) is pleased to announce the appointment of Andrew Maxwell as Non-Executive to the Medibio Board of Directors. It also announces the appointment of Franklyn G. Prendergast, M.D., Ph.D, a current Non Executive Director of Medibio, as Chairman of its Advisory Board.

Appointment of Andrew Maxwell as Non-Executive Director

Andrew brings a wealth of Medical Technology experience to the Board of Medibio. For 10 years, Andrew led the global growth of Global Kinetics Corporation Ltd (GKC) as Managing Director and Chief Executive Officer. GKC commercialised a research project emanating from the Florey Institute of Neuroscience and Mental Health and created a global company with a market-leading product for the remote measurement and reporting of the movement disorder symptoms of Parkinson's disease.

GKC gained FDA clearance in the USA, Class 1 and Class 2a CE mark in Europe and TGA registration in Australia for its Parkinson's KinetiGraph (PKG) and PKG Watch, a wearable medical device and a mobile health IT software system. GKC was the sponsor manufacture of product and via its own direct sales and marketing team implemented the PKG in over 140 hospitals in 16 countries providing more than 65,000 people with Parkinson's access to a clinical test that will make a meaningful difference to the management of their condition.

Prior to GKC, as CEO of ESCOR Private Equity (a Smorgon Family Company), Andrew established and managed a \$40m investment fund focused on investing in the IT, Internet, Biotech, and Healthcare sectors in Australia, the USA and Europe. Andrew was also a member of the ESCOR Group Investment Coordination Committee evaluating capital allocation and investments strategy for the ESCOR Group.

Advisory Board Changes

Medibio has reluctantly accepted the resignation of Mr Stephen Pearce as Chairman of its advisory Board. With the appointment of Stephen as Finance Director of Anglo American, including appointment to the Anglo Board as an Executive Director, and his move to London Stephen can no longer commit the time required to Chair Medibio's Advisory Board. The Company wishes Stephen well in his new role and values his ongoing involvement as supportive shareholder of Medibio.

Dr Franklyn Prendergast, a current Non Executive Director of Medibio, has agreed to take the role of Chair of Medibio's Advisory Committee. Frank has had a long and distinguished career in the US Healthcare industry with some of his more notable achievements including the role of director for research at Mayo

Clinic, member of the Board of Governors for Mayo Clinic and a member of Mayo Clinic's Executive Committee. He has been a member of the Eli Lilly Company Board of Directors since 1995 and has served extensively for the US National Institutes of Health in various capacities.

Dr Prendergast's vision is to use his extensive network in the US healthcare industry to expand Medibio's Advisory Board and use it as a platform to assist in the commercialisation of Medibio's technology for the diagnosis of depression and other mental Health Disorders.

-ends

Further Information:		Website: www.medibio.com.au
Medibio Shareholder Enquiries to: Kris Knauer CEO and Director Medibio Limited kris.knauer@medibio.com.au T: +61 (0)411 885979	Medibio Media Enquiries to: Peter Taylor NWR Communications peter@nwrcommunications.com.au T: +61 (0)412 036 231	

About Medibio Limited

Medibio (ASX: MEB), is a medical technology company that has developed an objective test to assist in the diagnosis of depression, chronic stress and other mental health disorders. Based on research conducted over 15 years at the University of Western Australia, this test utilizes patented (and patent pending) circadian heart rate variability and cloud based proprietary algorithms delivering a quantifiable measure to assist in clinical diagnosis. Medibio's depression diagnostic is being validated in clinical studies undertaken by Johns Hopkins University School of Medicine and The University of Ottawa, among others. The clinical trials will support Medibio's application to become the first FDA approved, objective, and evidence based approach to the diagnosis of mental health disorders. Medibio's technology also provides an objective method for the assessment of stress and mental wellbeing that can be translated to the workplace stress/wellbeing market, wearable technology and App market. Located in Melbourne (Vic) Medibio is listed on the Australian Securities Exchange Ltd.